Arcutis Biotherapeutics, Inc. (ARQT) Misses Q1 EPS by 3c

Arcutis Biotherapeutics, Inc. (NASDAQ: ARQT) reported Q1 EPS of ($1.31), $0.03 worse than the analyst estimate of ($1.28). Revenue for the quarter came in at $2.8 million versus the consensus estimate of $3.1 million.

For earnings history and earnings-related data on Arcutis Biotherapeutics, Inc. (ARQT) click here.

You May Also Be Interested In

• FDA Accepts Supplemental New Drug Application for Arcutis’ ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Mild to Moderate Atopic Dermatitis in Infants Down to 3 Months
• UBS Reiterates Neutral Rating on Carter's (CRI)
• Goldman Sachs Starts Contemporary Amperex Technology Co Ltd (300750:CH) at Buy